E
EW icon

Ergoteles’s Edwards Lifesciences EW Stock Holding History

Ergoteles’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-78,280
Closed -$7.44M – 1669
2022
Q2 		$7.44M Buy
+78,280
New +$8.1M 0.22% 120
2022
Q1 		– Sell
-7,668
Closed -$993K – 1344
2021
Q4 		$993K Buy
+7,668
New +$894K 0.04% 417
2021
Q3 		– Sell
-6,416
Closed -$665K – 1347
2021
Q2 		$665K Buy
+6,416
New +$605K 0.02% 667
2021
Q1 		– Sell
-12,352
Closed -$1.13M – 872
2020
Q4 		$1.13M Buy
+12,352
New +$1.02M 0.04% 314

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Ergoteles's EW Position: Q3 2022 in Review

Ergoteles sold out of Edwards Lifesciences (EW) in Q3 2022, closing a stake of 78,280 shares — an estimated $7.44M sold.

Ergoteles first reported a position in EW in Q4 2020 and held it in 4 quarters. The position peaked at $7.44M in Q2 2022. 1,246 funds tracked by Wall St. Rank hold EW as of Q3 2022.

  • Ergoteles reported no remaining Edwards Lifesciences position as of Q3 2022 after selling out during the quarter.
  • Ergoteles sold 78,280 Edwards Lifesciences shares in Q3 2022, an estimated $7.44M.
  • Ergoteles first reported a position in Edwards Lifesciences in Q4 2020 and held it in 4 quarters.
  • Ergoteles's Edwards Lifesciences position peaked at $7.44M in Q2 2022.
  • 1,246 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2022.

Based on Ergoteles's 13F filing for Q3 2022, filed 14 Nov 2022.